ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 154 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2019. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $318,000 | -47.2% | 10,100 | 0.0% | 0.17% | +138.0% |
| Q4 2019 | $602,000 | -74.7% | 10,100 | -84.4% | 0.07% | -76.6% |
| Q3 2019 | $2,379,000 | -79.9% | 64,900 | -74.5% | 0.30% | -63.0% |
| Q2 2019 | $11,848,000 | -24.5% | 254,700 | -34.8% | 0.82% | +13.1% |
| Q1 2019 | $15,694,000 | +50.2% | 390,900 | +72.1% | 0.73% | +0.8% |
| Q4 2018 | $10,446,000 | +89.9% | 227,100 | +83.1% | 0.72% | +128.6% |
| Q3 2018 | $5,501,000 | +74.2% | 124,000 | +53.8% | 0.32% | +70.3% |
| Q2 2018 | $3,158,000 | +0.6% | 80,600 | +85.7% | 0.18% | -8.0% |
| Q1 2018 | $3,139,000 | +817.8% | 43,400 | +73.6% | 0.20% | +240.7% |
| Q4 2013 | $342,000 | -48.7% | 25,000 | -29.4% | 0.06% | -61.2% |
| Q3 2013 | $667,000 | – | 35,400 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |